Clinical Trial Update: Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid [Phase 2]

View source ↗

Summary

Phase 2 trial of baricitinib for ocular mucous membrane pemphigoid was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cicatrizing Conjunctivitis
• Mucous Membrane Pemphigoid

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis | Phase 2 | Status: TERMINATED | Results posted: 2023-11-07